Drug resistance is a common problem in the treatment of multiple myeloma (MM), either through initial resistance to a drug, or a developed resistance associated with relapse. Speaking from the Myeloma 2017 meeting held in Edinburgh, UK, Brian Van Ness, PhD, of the University of Minnesota, Minneapolis, MN, outlines the talks given at the meeting regarding the problem of resistance, and the ways in which the MM community can address this issue.
Drug resistance in multiple myeloma: addressing the issue
